Changes in Causative Pathogens of Acute Cholangitis and Their Antimicrobial Susceptibility over a Period of 6 Years
Overview
Authors
Affiliations
Background/aims: We evaluated changes of causative pathogen in acute cholangitis and their antimicrobial susceptibility over six years and differences between community-acquired and hospital-acquired acute cholangitis at our institution.
Methods: Medical records of 1,596 patients with acute cholangitis and biliary drainage between August 2006 and August 2012 were reviewed retrospectively. Cases were divided according to time: period 1 (August 2006-December 2008, n=645, 40.4%), period 2 (January 2009-August 2012, n=951, 59.6%). Cases were divided according to community-acquired cholangitis (n=1,397, 87.5%) and hospital-acquired cholangitis (n=199, 12.5%). Causative pathogens and antimicrobial susceptibility were investigated in each group.
Results: Causative pathogen was isolated from bile culture in 1,520 out of 1,596 cases (95.2%). The three most frequently isolated Gram-negative bacteria were extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli (n=485, 30.4%), E. coli (n=237, 13.2%), and Citrobacter freundii (n=110, 6.9%). Between periods 1 and 2, prevalence of ESBL-producing E. coli and Klebsiella pneumoniae did not show significant change (36.7% vs. 32.1%, p=0.073; 6.6% vs. 6.2%, p=0.732). C. freundii showed a significant increase from period 1 to period 2 (1.7% vs. 13.2%, p=0.000). In both time periods, imipenem was the antimicrobial agent showing the highest rate of susceptibility (93.3% vs. 93.9%, p=0.783). Higher prevalence of ESBL-producing E. coli and C. freundii was observed in the hospital-acquired cholangitis group (52.1% vs. 31.2%, p=0.000; 15.9% vs. 7.3%, p=0.001).
Conclusions: The most common causative pathogen of acute cholangitis was ESBL-producing E. coli. Prevalence of C. freundii increased over the time period. Imipenem should be reserved as an alternative for resistant pathogens.
The role of microbes and parasites in recurrent pyogenic cholangitis.
Ansari Z, Ray S, Das S, Mandal T Turk J Surg. 2024; 40(2):154-160.
PMID: 39628502 PMC: 11610613. DOI: 10.47717/turkjsurg.2024.6364.
Liu T, Li M, Tang L, Wang B, Li T, Huang Y BMC Infect Dis. 2024; 24(1):1010.
PMID: 39300331 PMC: 11414084. DOI: 10.1186/s12879-024-09799-8.
Korean Guidelines for Use of Antibiotics for Intra-abdominal Infections in Adults.
Yoon Y, Moon C, Kim J, Heo S, Lee M, Lee S Infect Chemother. 2023; 54(4):812-853.
PMID: 36596690 PMC: 9840951. DOI: 10.3947/ic.2022.0156.
Jahn M, Ozcurumez M, Dolff S, Rohn H, Heider D, Dechene A J Clin Transl Hepatol. 2022; 10(5):788-795.
PMID: 36304501 PMC: 9547272. DOI: 10.14218/JCTH.2021.00337.
Zhao C, Liu S, Bai X, Song J, Fan Q, Chen J Evid Based Complement Alternat Med. 2022; 2022:9255444.
PMID: 35463066 PMC: 9020942. DOI: 10.1155/2022/9255444.